Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Milara, Javier ^a,b   Morell, Anselm ^a,c   Ballester, Bea ^c   Sanz, Celia ^d,e   Freire, Jose ^f   Qian, Xiaozhong ^f   Alonso Garcia, Maggie ^f   Morcillo, Esteban ^c   Cortijo, Julio ^a,b,c  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^e Valencia Transfusion Center   (Spain)

^f FOREST RESEARCH INSTITUTE   (United States)

Author keywords

COPD; Corticosteroid resistance; Roflimilast; Toll like receptors; Viral exacerbation

Indexed keywords

DEXAMETHASONE; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYINOSINIC POLYCYTIDYLIC ACID; ROFLUMILAST; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRANSCRIPTION FACTOR AP 1; AMINOPYRIDINE DERIVATIVE; ANTIINFLAMMATORY AGENT; BENZAMIDE DERIVATIVE; CORTICOSTEROID; CYCLOPROPANE DERIVATIVE; IL8 PROTEIN, HUMAN; ROFLUMILAST N-OXIDE; TLR3 PROTEIN, HUMAN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CELL STIMULATION; CELL VIABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EPITHELIUM CELL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; LUNG PARENCHYMA; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMOKING; UPREGULATION; ADVERSE EFFECTS; AGONISTS; BRONCHUS; CASE CONTROL STUDY; CELL CULTURE; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION;

ADRENAL CORTEX HORMONES; AGED; AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; BRONCHI; CASE-CONTROL STUDIES; CELLS, CULTURED; CYCLOPROPANES; DEXAMETHASONE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPITHELIAL CELLS; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; POLY I-C; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION; SMOKING; TOLL-LIKE RECEPTOR 3;

EID: 84927769997     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0179-5     Document Type: Article

References (44)

1. Sethi S, Mahler DA, Marcus P, Owen CA, Yawn B, Rennard S. Inflammation in COPD: implications for management. Am J Med 2012, 125(12):1162-70. 10.1016/j.amjmed.2012.06.024, 23164484.
2. Roche N, Marthan R, Berger P, Chambellan A, Chanez P, Aguilaniu B, et al. Beyond corticosteroids: future prospects in the management of inflammation in COPD. Eur Respir Rev 2011, 20(121):175-82. 10.1183/09059180.00004211, 21881145.
3. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010, 23(4):235-56. 10.1016/j.pupt.2010.03.011, 20381629.
4. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007, 370(9589):786-96. 10.1016/S0140-6736(07)61382-8, 17765528.
5. Farr BM, Gwaltney JM, Hendley JO, Hayden FG, Naclerio RM, McBride T, et al. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis 1990, 162(5):1173-7. 10.1093/infdis/162.5.1173, 2172395.
6. Papi A, Contoli M, Adcock IM, Bellettato C, Padovani A, Casolari P, et al. Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor kappaB and c-Jun N-terminal kinase activation. J Allergy Clin Immunol 2013, 132(5):1075-85. e1076, 10.1016/j.jaci.2013.05.028, 23871663.
7. Bauer CM, Zavitz CC, Botelho FM, Lambert KN, Brown EG, Mossman KL, et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One 2010, 5(10):e13251. 10.1371/journal.pone.0013251, 20967263.
8. Kimura G, Ueda K, Eto S, Watanabe Y, Masuko T, Kusama T, et al. Toll-like receptor 3 stimulation causes corticosteroid-refractory airway neutrophilia and hyperresponsiveness in mice. Chest 2013, 144(1):99-105. 10.1378/chest.12-2610, 23348232.
9. Mata M, Martinez I, Melero JA, Tenor H, Cortijo J. Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells. PLoS One 2013, 8(7):e69670. 10.1371/journal.pone.0069670, 23936072.
10. Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014, 134(2):314-22. 10.1016/j.jaci.2014.02.001, 24636089.
11. Gern JE, Vrtis R, Grindle KA, Swenson C, Busse WW. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med 2000, 162(6):2226-31. 10.1164/ajrccm.162.6.2003019, 11112143.
12. Jafri HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nassi SS, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 2004, 189(10):1856-65. 10.1086/386372, 15122522.
13. McNamara PS, Flanagan BF, Hart CA, Smyth RL. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 2005, 191(8):1225-32. 10.1086/428855, 15776367.
14. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006, 61(3):250-8. 10.1136/thx.2005.041822, 16517585.
15. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005, 280(7):5571-80. 10.1074/jbc.M410592200, 15579900.
16. Freeman CM, Martinez FJ, Han MK, Washko GR, McCubbrey AL, Chensue SW, et al. Lung CD8+ T cells in COPD have increased expression of bacterial TLRs. Respir Res 2013, 14:13. 10.1186/1465-9921-14-13, 23374856.
17. Koarai A, Yanagisawa S, Sugiura H, Ichikawa T, Akamatsu K, Hirano T, et al. Cigarette smoke augments the expression and responses of toll-like receptor 3 in human macrophages. Respirology 2012, 17(6):1018-25. 10.1111/j.1440-1843.2012.02198.x, 22591330.
18. Sukkar MB, Xie S, Khorasani NM, Kon OM, Stanbridge R, Issa R, et al. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J Allergy Clin Immunol 2006, 118(3):641-8. 10.1016/j.jaci.2006.05.013, 16950283.
19. Todt JC, Freeman CM, Brown JP, Sonstein J, Ames TM, McCubbrey AL, et al. Smoking decreases the response of human lung macrophages to double-stranded RNA by reducing TLR3 expression. Respir Res 2013, 14:33. 10.1186/1465-9921-14-33, 23497334.
20. Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008, 60(7):813-23. 10.1016/j.addr.2007.11.004, 18241955.
21. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18. 10.1186/1465-9921-12-18, 21272339.
22. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-55. 10.1164/rccm.200703-456SO, 17507545.
23. Milara J, Armengot M, Banuls P, Tenor H, Beume R, Artigues E, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro . Br J Pharmacol 2012, 166(8):2243-62. 10.1111/j.1476-5381.2012.01929.x, 22385203.
24. Ortiz JL, Milara J, Juan G, Montesinos JL, Mata M, Ramon M, et al. Direct effect of cigarette smoke on human pulmonary artery tension. Pulm Pharmacol Ther 2010, 23(3):222-8. 10.1016/j.pupt.2009.11.001, 19931631.
25. Milara J, Peiro T, Serrano A, Cortijo J. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax 2013, 68(5):410-20. 10.1136/thoraxjnl-2012-201761, 23299965.
26. Milara J, Ortiz JL, Juan G, Guijarro R, Almudever P, Martorell M, et al. Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences. Br J Pharmacol 2010, 161(7):1599-615. 10.1111/j.1476-5381.2010.00979.x, 20698855.
27. Su Y, Han W, Giraldo C, De Li Y, Block ER. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1998, 19(5):819-25. 10.1165/ajrcmb.19.5.3091, 9806747.
28. Koarai A, Sugiura H, Yanagisawa S, Ichikawa T, Minakata Y, Matsunaga K, et al. Oxidative stress enhances toll-like receptor 3 response to double-stranded RNA in airway epithelial cells. Am J Respir Cell Mol Biol 2010, 42(6):651-60. 10.1165/rcmb.2008-0345OC, 19597128.
29. Ohkuni T, Kojima T, Ogasawara N, Masaki T, Fuchimoto J, Kamekura R, et al. Poly(I:C) reduces expression of JAM-A and induces secretion of IL-8 and TNF-alpha via distinct NF-kappaB pathways in human nasal epithelial cells. Toxicol Appl Pharmacol 2011, 250(1):29-38. 10.1016/j.taap.2010.09.023, 20932985.
30. Bethke TD, Bohmer GM, Hermann R, Hauns B, Fux R, Morike K, et al. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007, 47(1):26-36. 10.1177/0091270006294529, 17192499.
31. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro . J Pharmacol Exp Ther 2001, 297(1):267-79. 11259554.
32. Kinose D, Ogawa E, Kudo M, Marumo S, Kiyokawa H, Hoshino Y, et al. Association of COPD exacerbation frequency with gene expression of pattern recognition receptors in inflammatory cells in induced sputum. Clin Respir J. 2014. doi:10.1111/crj.12171..
33. Wortham BW, Eppert BL, Flury JL, Morgado Garcia S, Borchers MT. TLR and NKG2D signaling pathways mediate CS-induced pulmonary pathologies. PLoS One 2013, 8(10):e78735. 10.1371/journal.pone.0078735, 24130907.
34. Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, Hunninghake GW. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 2006, 176(3):1733-40. 10.4049/jimmunol.176.3.1733, 16424203.
35. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013, 131(3):636-45. 10.1016/j.jaci.2012.12.1564, 23360759.
36. Chi XY, Jiang SJ, Wang J, Wang JP. Effect of glucocorticoid in mice of asthma induced by ovalbumin sensitisation and RSV infection. Asian Pac J Allergy Immunol 2011, 29(2):176-80. 21980833.
37. Heijink I, van Oosterhout A, Kliphuis N, Jonker M, Hoffmann R, Telenga E, et al. Oxidant-induced corticosteroid unresponsiveness in human bronchial epithelial cells. Thorax 2014, 69(1):5-13. 10.1136/thoraxjnl-2013-203520, 23980116.
38. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010, 120(2-3):76-85. 10.1016/j.jsbmb.2010.02.018, 20188830.
39. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 1997, 121(2):221-31. 10.1038/sj.bjp.0701124, 9154331.
40. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, et al. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 1995, 25(7):625-33. 10.1111/j.1365-2222.1995.tb01110.x, 8521181.
41. Moodley T, Wilson SM, Joshi T, Rider CF, Sharma P, Yan D, et al. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease. Mol Pharmacol 2013, 83(4):894-906. 10.1124/mol.112.083493, 23389862.
42. Tannheimer SL, Sorensen EA, Haran AC, Mansfield CN, Wright CD, Salmon M. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells. Pulm Pharmacol Ther 2012, 25(2):178-84. 10.1016/j.pupt.2012.01.003, 22306235.
43. Rider CF, King EM, Holden NS, Giembycz MA, Newton R. Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: rescue by long-acting beta2-adrenoceptor agonists. J Pharmacol Exp Ther 2011, 338(3):860-9. 10.1124/jpet.111.181016, 21622733.
44. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Mullerova H, Donaldson GC, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29(3):527-34. 10.1183/09031936.00092506, 17107990.